Summary
This multicentre open 6-week study evaluated the efficacy, safety and tolerability of fluvastatin, the first fully synthetic 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitor, in elderly women with type IIa hypercholesterolemia. After a 4-week single-blind placebo period, 22 elderly women (mean age 68 ± 5 years) with primary hypercholesterolemia [low density lipoprotein (LDL) cholesterol > 160 mg/dl] were enrolled in the trial. Fluvastatin 40mg was administered once in the evening. At baseline, and after 3 and 6 weeks of treatment, total cholesterol, LDL cholesterol, high density lipoprotein (HDL) cholesterol, triglycerides, apolipoproteins B (apo B) and A-I (apo A-I) were measured. Safety and tolerability were assessed by monitoring routine laboratory parameters and by recording spontaneously reported side effects. The mean (± SD) baseline total cholesterol, LDL cholesterol, triglyceride, HDL cholesterol, apo B and apo A-I levels were 325 ± 43, 236 ± 43, 128 ± 56, 61 ± 16, 221 ± 60 and 164 ± 28 mg/dl, respectively.
After 6 weeks, fluvastatin significantly (p < 0.001, ANOVA test) reduced total cholesterol, LDL cholesterol and apo B levels by 22%, 29% and 23%, respectively. These significant reductions were already reached at week 3 (total cholesterol, −21%; LDL cholesterol, −27%). The total cholesterol: HDL cholesterol ratio was reduced by 22% at week 3 and by 21% at week 6 (from 5.3 to 4.2). 78% of the patients showed a reduction ⩾ 20% for LDL cholesterol. Triglycerides were reduced by 16% (not significant). No clinically significant modifications in safety parameters or in the plasma concentrations of aspartate and alanine amino transferases, or creatine Phosphokinase were observed during the study. Mild and transient drug-related side effects (gastrointestinal complaints) were reported in 2 cases. No patient discontinued the study because of adverse events. Muscle-related symptoms were not reported.
Thus, fluvastatin 40mg once daily is efficacious, safe and well tolerated in the treatment of primary hypercholesterolaemia in elderly women.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Baggio G. Italian pravastatin study in the elderly (IPSE) group: pravastatin versus bezafibrate treatment in elderly hypercho-lesterolemic patients. Arteriosclerosis and Thrombosis 11: 1509, 1991
Bush TL. The epidemiology of cardiovascular disease in postmenopausal women. Annals of the New York Academy of Science 592: 263–271, 1990
Bush TL. The epidemiology of cardiovascular disease in older persons. Aging — Clinical and Experimental Research 3: 3–8, 1991
Denke MA, Grundy SM. Hypercholesterolemia in elderly persons: resolving the treatment dilemma. Annals of Internal Medicine 112: 780–792, 1990
Eisenberg JM. Should the elderly be screened for hypercholesterolemia? Archives of Internal Medicine 151: 1063–1065, 1991
European Study Group. Efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolemia. American Journal of Cardiology 70: 1281–1286, 1992
Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dys-lipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. New England Journal of Medicine 317: 1237–1245, 1987
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative centrifuge. Clinical Chemistry 18: 499–502, 1972
Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Annals of Internal Medicine 90: 85–91, 1979
Kathawala FG. HMG-CoA reductase inhibitors: an exciting development in the treatment of hyperlipoproteinemia. Medicinal Research Reviews 11: 121–146, 1991
Klein HH, Hengstenberg C, Peuckert M, Jürgensen R. Comparison of death rates from acute myocardial infarction in a single hospital in two different periods. American Journal of Cardiology 71: 518–523, 1993
Kwiterovich PO, Kafonek SD. Treatment of hypercholesterolemia in the elderly. Annals of Internal Medicine 112: 723–725, 1990
Leitersdorf E, Eisenberg S, Eliav O, Friedlander Y, Berkman N, et al. Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia. Circulation 87 (Suppl. III): 35–44, 1993
Levy RI, Troendle AJ, Fattu JM. A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin. Circulation 87 (Suppl. III): 45–53, 1993
Lintott CJ, Scott RS. HMG-CoA reductase inhibitor use in the aged. A review of clinical experience. Drugs and Aging 2: 518–529, 1992
Lipid Research Clinics Coronary Primary Prevention Trial Results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. Journal of the American Medical Association 251: 365–374, 1984
Mol MJ, Stalenhoef AF. HMG-CoA reductase inhibitors. Current Opinion in Lipidology 4: 41–48, 1993
Oster G, Epstein AM. Primary prevention and coronary heart disease: the economy benefits of lowering serum cholesterol. American Journal of Public Health 76: 647–656, 1986
Prous J, Castaner J. Fluvastatin sodium. Drugs of the Future 16: 804–810, 1991
Rubin SM, Sidney S, Black DM, Browner WS, Hulley SB, et al. High blood cholesterol in elderly men and the excess risk for coronary heart disease. Annals of Internal Medicine 113: 916–920, 1990
Shipley MJ, Pocock SJ, Marmot MG. Does plasma cholesterol concentration predict mortality from coronary heart disease in elderly people? 18 year follow up in Whitehall study. British Medical Journal 303: 89–92, 1991
Task Force on Cholesterol. Task Force on Cholesterol Issues, American Heart Association. The cholesterol facts. Circulation 81: 1721–1733, 1990
Tse FLS, Jaffe JM, Troendle A. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. Journal of Clinical Pharmacology 32: 630–638, 1992
Walker JF, Pingeon RA, Shapiro DA. Efficacy and tolerability of simvastatin (epistatin) in the elderly. Drug Investigation 2 (Suppl. 2): 53–56, 1990
Wenger NK, Speroff L, Packard B. Cardiovascular health and disease in women. New England Journal of Medicine 329: 247–250, 1993
Yuan J, Tsai MY, Hegland J, Hunninghake DB. Effects of fluvastatin (XU 62–320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans. Atherosclerosis 87: 147–157, 1991
Zimetbaum P, Frishman WH, Ooi WL, Derman MP, Aronson M, et al. Plasma lipids and lipoproteins and the incidence of cardiovascular disease in the very elderly. Arteriosclerosis and Thrombosis 12: 416–423, 1992
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Baggio, G., De Candia, O., Forte, P.L. et al. Efficacy and Safety of Fluvastatin, a New HMG CoA Reductase Inhibitor, in Elderly Hypercholesterolaemic Women. Drugs 47 (Suppl 2), 59–63 (1994). https://doi.org/10.2165/00003495-199400472-00011
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199400472-00011